Welcome to our dedicated page for Axsome Therapeutics news (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics stock.
Axsome Therapeutics, Inc. reports news on its biopharmaceutical business focused on central nervous system disorders, including marketed medicines and late-stage neuroscience programs. Company updates commonly cover FDA actions, product revenue for AUVELITY, SUNOSI and SYMBRAVO, business results, investor presentations, and development activity in neurological and psychiatric conditions.
Recurring topics include AUVELITY for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease, SUNOSI for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, migraine treatment commercialization, and pipeline work involving solriamfetol, AXS-12 and PDE10A inhibitor programs.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will participate in two investor conferences: the William Blair 40th Annual Growth Stock Conference on June 9, 2020, at 1:20 PM CT, and the SVB Leerink CybeRx Series: 2nd Annual CNS Forum on June 23, 2020, at 2:45 PM ET. Both events will feature virtual fireside chats with CEO Herriot Tabuteau. Interested parties can access the live webcast of the William Blair event on the company’s website. Axsome focuses on developing novel therapies for central nervous system disorders, with a portfolio that includes multiple clinical-stage candidates.
Summary not available.
Summary not available.